Goldberg Hilary J, Fiedler Douglas, Webb Amy, Jagirdar Jashiree, Hoyumpa Anastacio M, Peters Jay
Brigham and Womens' Hospital, Division of Pulmonary and Critical Care Medicine, Department of Medicine, Harvard University School of Medicine, PBB Clinics-3, 75 Francis St., Boston, MA 02115, USA.
Respir Med. 2006 Nov;100(11):2063-8. doi: 10.1016/j.rmed.2006.03.004. Epub 2006 May 3.
Recombinant interferon-alpha (rINF-alpha) is an immunomodulator used in the treatment of various conditions, including viral infections and malignancies. The use of rINF-alpha has been associated with the development of sarcoidosis in recent case reports. In this series, we report the incidence of sarcoidosis in recipients of rINF-alpha for hepatitis C viral (HCV) infection at our institution. We also review the 57 additional cases of sarcoidosis associated with rINF-alpha described in the literature, including clinical presentation, radiographic findings, management, and outcomes, and discuss the potential mechanisms by which rINF-alpha may lead to the development of sarcoidosis.
重组干扰素-α（rINF-α）是一种免疫调节剂，用于治疗多种病症，包括病毒感染和恶性肿瘤。近期的病例报告显示，使用rINF-α与结节病的发生有关。在本系列研究中，我们报告了在我们机构接受rINF-α治疗丙型肝炎病毒（HCV）感染的患者中结节病的发生率。我们还回顾了文献中描述的另外57例与rINF-α相关的结节病病例，包括临床表现、影像学检查结果、治疗及预后，并探讨了rINF-α可能导致结节病发生的潜在机制。
